B2 Thymoma, Thymic Carcinoma
Conditions
Keywords
CAR-NK, Natural killer cells, Adoptive cell therapy, Thymic epithelial tumor, CD30, CD5, Mesothelin, Biomarker-guided, Solid tumor immunotherapy
Brief summary
This Phase 1/2 study evaluates the safety, tolerability, and preliminary efficacy of target-selected CAR-natural killer (CAR-NK) cells in adults with relapsed or refractory B2 thymoma or thymic carcinoma. Participants undergo centralized tumor antigen assessment (CD30, CD5, and mesothelin). Based on the dominant and clinically actionable antigen expression profile, each participant is assigned to one of three parallel cohorts (CD30-CAR-NK, CD5-CAR-NK, or mesothelin-CAR-NK). All cohorts use the same lymphodepleting conditioning regimen followed by CAR-NK infusion(s).
Detailed description
This is a first-in-indication, open-label, non-randomized, multi-center Phase 1/2 study with biomarker-driven cohort assignment. Phase 1 (dose escalation): Within each target cohort, a standard 3+3 dose-escalation design evaluates up to three dose levels of the assigned CAR-NK product to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D). Dose-limiting toxicities (DLTs) are assessed from Day 0 through Day 28 after the first CAR-NK infusion. Phase 2 (dose expansion): After an RP2D is identified in a cohort, an expansion stage enrolls additional participants in that cohort to further characterize safety and estimate preliminary antitumor activity. CAR-NK product: Off-the-shelf, allogeneic cord blood-derived NK cells are genetically modified to express a single-target CAR (anti-CD30, anti-CD5, or anti-mesothelin). The construct includes an IL-15 support element to enhance persistence and an inducible caspase-9 (iCasp9) safety switch for rapid elimination of CAR-NK cells if clinically indicated. Correlative studies: Serial blood and (when feasible) tumor sampling will evaluate CAR-NK persistence, immune activation markers, cytokines, tumor antigen modulation, and exploratory biomarkers of response and resistance. Long-term follow-up: Participants will be followed for delayed adverse events and survival; participants receiving gene-modified cells will also be invited to long-term follow-up consistent with applicable gene therapy guidance.
Interventions
DRUGCyclophosphamide
lymphodepletion
DRUGFludarabine
lymphodepletion
BIOLOGICALEB-CAR30-NK
CD30-targeted allogeneic CAR-NK cells
BIOLOGICALEB-CAR5-NK
CD5-targeted allogeneic CAR-NK cells
BIOLOGICALEB-CARMSLN-NK
Mesothelin-targeted allogeneic CAR-NK cells
ctivate the iCasp9 safety switch if clinically indicated
Sponsors
Beijing Biotech
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
This is an open-label study; participants and investigators know the assigned cohort and treatment.
Intervention model description
Participants are assigned to one of three CAR-NK target cohorts based on centralized tumor antigen expression testing (CD30, CD5, mesothelin). Each cohort uses a Phase 1 dose-escalation stage followed by a Phase 2 expansion stage.
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age 18 to 75 years at the time of consent. * Histologically confirmed B2 thymoma or thymic carcinoma that is unresectable, metastatic, or recurrent. * Relapsed or refractory after at least 1 prior systemic therapy (including a platinum-based regimen for thymic carcinoma when appropriate) or no standard curative option available. * Tumor antigen positivity for at least one of the following by central laboratory assessment: CD30, CD5, or mesothelin. Cohort assignment is based on the dominant target (pre-specified algorithm) and feasibility of manufacturing/availability. * Measurable disease per RECIST v1.1 (or evaluable disease if measurable disease is not feasible; to be specified). * ECOG performance status 0-1 (0-2 may be permitted in expansion at investigator discretion). * Adequate organ function: ANC ≥ 1.0 x 10\^9/L, platelets ≥ 75 x 10\^9/L, hemoglobin ≥ 8 g/dL (transfusions allowed), AST/ALT ≤ 3 x ULN (≤ 5 x ULN with liver involvement), total bilirubin ≤ 1.5 x ULN (except Gilbert's), creatinine clearance ≥ 50 mL/min. * Negative pregnancy test for participants of childbearing potential; agreement to use effective contraception. * Ability to understand and sign informed consent.
Exclusion criteria
* Active central nervous system involvement by malignancy requiring immediate therapy. * Prior gene-modified cellular therapy (e.g., CAR-T, CAR-NK) within 90 days or unresolved ≥Grade 2 toxicity from prior cellular therapy. * Uncontrolled infection, including active tuberculosis, or uncontrolled hepatitis B or C infection; known uncontrolled HIV infection. * Clinically significant autoimmune disease requiring systemic immunosuppression (e.g., \>10 mg/day prednisone equivalent) within 14 days of conditioning, except for stable endocrine replacement. * Prior allogeneic hematopoietic stem cell transplant with active graft-versus-host disease or ongoing immunosuppression. * Significant cardiovascular disease (e.g., NYHA class III/IV heart failure, recent myocardial infarction), uncontrolled arrhythmia, or QTc prolongation felt to increase risk. * Pregnancy or breastfeeding. * Concurrent participation in another interventional trial with an investigational anticancer agent within 21 days (washout required). * Any condition that, in the investigator's judgment, would interfere with safe participation or interpretation of results.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Dose-Limiting Toxicities (DLTs) | 28 Days | DLTs as defined in protocol, assessed during the DLT window after the first CAR-NK infusion. Includes severe infusion-related toxicity, Grade \>=3 organ toxicity attributable to CAR-NK cells, severe CRS or neurotoxicity, and treatment-related death. |
| Recommended Phase 2 Dose | 28 Days | Determined separately for each cohort based on DLTs, overall safety, and pharmacodynamic data |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 12 months | Proportion of participants with complete response (CR) or partial response (PR) per RECIST v1.1 (or modified criteria appropriate for thymic tumors) in each cohort. |
| Disease Control Rate | 12 months | Proportion of participants with CR, PR, or stable disease |
Countries
China
Contacts
CONTACTSeni S Lu, Phd
Outcome results
None listed